Theriva Biologics Inc (TOVX)

[Ann1]

Yes, it is like investing in two different companies! Except for two constants - Trimesta and Effirma. I initially invested on Trimesta. I liked the data, the prospects, etc. for MS. And I really thought Dr. Voskuhl a very bright and determined lady -- she has been at this for a LONG time and deserves a big hit! There are some employees there who have been around for awhile as well, like the gal in communications -- and I like them too.

Back in the AEN days, they seemed to get off track with the zinc stuff. When Kirk and his management team came on board, there was a big re-focus on cutting edge therapies (all the synthetic/beta lactamase stuff -- the don't kill it, make it work for you thinking sounded really, really good). After I did my DD on the science, I was stoked. Here I was investing in Trimesta and LOOK what I got instead! :) So, yes, been buying ever since. Kirk is no slouch when it comes to investing in biotechs. If he's in, I'm in.

Alone, Trimesta makes SYN worth north of $5. And yet there is so much more to offer investors now. At this PPS, it is such a no-brainer, IMO. Folks are just beginning to notice.

GLTU